{
  "type": "add_node",
  "timestamp": "2025-08-14T23:50:09",
  "processed": false,
  "inputs": {
    "source_article_id": "8I40VPCE9",
    "status": "rejected",
    "reject_category": "asset",
    "reject_failure_cat": "industry_vertical"
  },
  "details": {
    "llm_topic_proposal_raw": {
      "motivation": "The article highlights the development and regulatory pathway of VYD2311, a monoclonal antibody candidate aimed at COVID-19 prevention, which is crucial for understanding macro-level health impacts and investment opportunities in biopharmaceuticals.",
      "id": "vyd2311",
      "name": "VYD2311",
      "type": "asset",
      "level": "main"
    },
    "topic_category": {
      "category": "asset",
      "motivation": "VYD2311 is a specific monoclonal antibody candidate, making it an asset."
    },
    "relevance_gate": {
      "should_add": false,
      "reason": "VYD2311 is a specific monoclonal antibody product, a micro-level biopharma asset, not a macro driver or tradable instrument; it falls under industry verticals, which are disallowed.",
      "confidence": 0.95,
      "failure_category": "industry_vertical"
    }
  },
  "id": "none"
}